Cargando…
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting
To characterize determinants of treatment outcome in a real world population of 161 post-menopausal hormone receptor-positive metastatic breast cancer patients treated with fulvestrant. Descriptive statistics for demographics, anthropometrics, clinical and molecular characteristic were compared acro...
Autores principales: | Pizzuti, Laura, Natoli, Clara, Gamucci, Teresa, Mauri, Mariella, Sergi, Domenico, Di Lauro, Luigi, Paoletti, Giancarlo, Ruggeri, Enzo, Iezzi, Laura, Sperduti, Isabella, Mentuccia, Lucia, Fabbri, Agnese, Maugeri-Saccà, Marcello, Moscetti, Luca, Barba, Maddalena, Vici, Patrizia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620318/ https://www.ncbi.nlm.nih.gov/pubmed/28978178 http://dx.doi.org/10.18632/oncotarget.16982 |
Ejemplares similares
-
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017) -
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014) -
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
por: Barba, Maddalena, et al.
Publicado: (2017) -
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018) -
Optimal tolerability and high efficacy of a modified schedule of lapatinib–capecitabine in advanced breast cancer patients
por: Gamucci, T., et al.
Publicado: (2013)